Posts about

Syndicated Studies

CMV: current management and opportunities for future treatments for Cytomegalovirus

hemato-oncology, Syndicated Studies, CMV, Infectiology

New in 2023 !

MDS: Treatment paradigms are changing

hemato-oncology, Tracking Studies, Syndicated Studies, Oncology

MyeloDysplastic Syndromes: our syndicated research will tell you why - and how - treatment...

Our brand new 2020 Syndicated Surveys

COVID-19, Syndicated Studies

Our range of syndicated studies now covers over 30 indications, many of them with results already...

COVID-19 2nd Phase - Impact on Physicians’ Practice - Syndicated Study

COVID-19, Syndicated Studies

How does COVID-19 affect the HCPS relationships with patients and with the pharmaceutical industry?...

mRCC: promising new combinations lead to disruption in L1 and L2

Syndicated Studies, Oncology

Targeted therapies, particularly tyrosine kinase inhibitors (TKI) dominate the treatment of...

COVID-19 road to recovery: 5 key insights from our syndicated study

COVID-19, Syndicated Studies

As the global number of infected cases surpasses 46 million (Nov 2, 2020), there is a non-stop...

DLBCL Patient Insights in the US and EU5

hemato-oncology, Tracking Studies, DLBCL market, Syndicated Studies

When working on a new or existing brand within the DLBCL market it's important to have up to date...

DLBCL Treatment Performance in EU5 and US

hemato-oncology, Tracking Studies, DLBCL market, Syndicated Studies

The DLBCL market is undergoing a period of change, and the relative performance of the various...

DLBCL Market Overview

hemato-oncology, Tracking Studies, DLBCL market, Syndicated Studies, Oncology

Following the release of our latest ebook, this is the first blog post in this series focusing on...

New AplusA eBook Covers the DLBCL Market

AplusA News, hemato-oncology, Tracking Studies, DLBCL market, Syndicated Studies, Oncology

Introducing the latest eBook in AplusA's Hemato-Oncology series